Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Common Equity (2016 - 2025)

Historic Common Equity for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $14.9 million.

  • Heron Therapeutics' Common Equity rose 13720.78% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 13720.78%. This contributed to the annual value of -$33.7 million for FY2024, which is 94.78% up from last year.
  • As of Q3 2025, Heron Therapeutics' Common Equity stood at $14.9 million, which was up 13720.78% from -$27.3 million recorded in Q2 2025.
  • Heron Therapeutics' Common Equity's 5-year high stood at $196.2 million during Q1 2021, with a 5-year trough of -$40.0 million in Q3 2024.
  • For the 5-year period, Heron Therapeutics' Common Equity averaged around $15.4 million, with its median value being -$21.7 million (2022).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 35031.68% in 2023, then surged by 13720.78% in 2025.
  • Over the past 5 years, Heron Therapeutics' Common Equity (Quarter) stood at $77.6 million in 2021, then crashed by 82.5% to $13.6 million in 2022, then tumbled by 350.32% to -$34.0 million in 2023, then grew by 0.95% to -$33.7 million in 2024, then skyrocketed by 144.23% to $14.9 million in 2025.
  • Its Common Equity was $14.9 million in Q3 2025, compared to -$27.3 million in Q2 2025 and -$28.5 million in Q1 2025.